What's in American Regent, Inc.'s pipeline?

American Regent, Inc. has 14 drugs in our index: 5 marketed, 0 filed, 6 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with American Regent, Inc.'s portfolio?

Top competitors by shared drug class: Rockwell Medical Technologies, Inc., Ain Shams University, China-Japan Friendship Hospital, Azad Pharma AG, CN NGANOU-GNINDJIO, MD, MSc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/american-regent-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

American Regent, Inc. — Portfolio Competitive Intelligence Brief

American Regent, Inc. pipeline: 5 marketed, 0 filed, 6 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 6 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Ferrous Sulfate tablets	Ferrous Sulfate tablets	marketed
Venofer® 200 mg	Venofer® 200 mg	marketed
Ferric Carboxymaltose (FCM)	Ferric Carboxymaltose (FCM)	marketed	Intravenous iron replacement agent	Iron (Fe³⁺) delivery; transferrin and ferritin binding	Hematology
Iron Sucrose (Venofer)	Iron Sucrose (Venofer)	marketed	Intravenous iron replacement agent		Hematology
Tralement	Tralement	marketed			Other
Iron Sucrose + Erythropoietin	Iron Sucrose + Erythropoietin	phase 3	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Iron (ferric hydroxide complex) + Erythropoietin receptor (EPOR)	Hematology / Nephrology
Oral Iron + Erythropoietin	Oral Iron + Erythropoietin	phase 3	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Iron (Fe2+/Fe3+) and erythropoietin receptor (EPOR)	Hematology
iron sucrose injection USP	iron sucrose injection USP	phase 3	Iron replacement agent	Iron (Fe3+) delivery; transferrin receptor-mediated uptake	Hematology
stable erythropoietin therapy	stable erythropoietin therapy	phase 3	erythropoiesis-stimulating agent	erythropoietin receptor	Hematology
Standard Medical Care (SMC)	Standard Medical Care (SMC)	phase 3
VIT-45	VIT-45	phase 3	Vitamin D analog	Vitamin D receptor (VDR)	Immunology

Therapeutic area mix

Hematology · 5
Other · 2
Hematology / Nephrology · 1
Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Rockwell Medical Technologies, Inc. · 2 shared drug classes
Ain Shams University · 1 shared drug class
China-Japan Friendship Hospital · 1 shared drug class
Azad Pharma AG · 1 shared drug class
CN NGANOU-GNINDJIO, MD, MSc · 1 shared drug class
Centre Francois Baclesse · 1 shared drug class
Albina Nowak, MD · 1 shared drug class
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for American Regent, Inc.:

Cite this brief

Drug Landscape (2026). American Regent, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/american-regent-inc. Accessed 2026-05-16.